About Scribe Therapeutics
Scribe Therapeutics is a company based in Alameda (United States) founded in 2018 by Jennifer A Doudna, Brett T Staahl, and David F Savage. Scribe Therapeutics has raised $120 million across 2 funding rounds from investors including T. Rowe Price, Orbimed and RA Capital. Scribe Therapeutics offers products and services including CRISPR-based Therapeutics and Epigenetic Long-Term X-Repressor Technology. Scribe Therapeutics operates in a competitive market with competitors including Beam Therapeutics, eGenesis, Korro Bio, Metagenomi and Prime Medicine, among others.
- Headquarter Alameda, United States
- Founders Jennifer A Doudna, Brett T Staahl, David F Savage
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website scribetx.com
- Social LinkedIn X
- Legal Name Scribe Therapeutics Inc.
- Total Equity Funding$120M (USD)
in 2 rounds
- Latest Funding Round$100M (USD), Series B
Mar 2021
- InvestorsT. Rowe Price
& 7 more
Products & Services of Scribe Therapeutics
Scribe Therapeutics offers a comprehensive portfolio of products and services, including CRISPR-based Therapeutics and Epigenetic Long-Term X-Repressor Technology.
Engineers CRISPR systems for safe treatment of genetic diseases.
Develops technology for long-term genetic regulation in disease management.
Funding Insights of Scribe Therapeutics
Scribe Therapeutics has successfully raised a total of $120M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $120M
- Total Rounds 2
- Last Round Series B — $100M
- First Round $20M
(Oct 2020)
- Investors Count 8
All 2 funding rounds of Scribe Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $100M | Series B | – | Avoro Capital Advisors | |
| Oct 2020 | $20M | Series A | – | a16z | – |
8 investors in total: 8 institutional.
Investors in Scribe Therapeutics
Scribe Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include T. Rowe Price, Orbimed and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on biotechnology startups | – | avorocapital.com | New York, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | – | a16z.com | - | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Early-stage venture capital firm investing in AI, healthcare, and tech sectors. | – | menlovc.com | - | |
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Diversified investment management services are provided to institutional clients. | – | wellington.com | Boston, United States |
Investor details for Scribe Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Scribe Therapeutics
31 people are tracked at Scribe Therapeutics (20 in leadership, 2 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Jennifer A Doudna | Co-Founder & Scientific Advisor | Leadership |
Brett T Staahl | Co-Founder | Leadership |
David F Savage | Co-Founder & Scientific Advisor | Leadership |
Ed Sterling II | Director, Information Technology At Scribe Therapeutics | Leadership |
Benjamin L. Oakes | Co-Founder, President & CEO | Leadership |
Svetlana Lucas | Chief Business Officer | Leadership |
Vera Switek | VP, Talent | Leadership |
David Parrot | CFO | Leadership |
Maria Mirotsou | Senior Vice President, Discovery | Leadership |
Shilpa Shroff | VP, Process Sciences | Leadership |
George Manning, BA, FCA | Vp, Controller | Leadership |
Ioana L. Aanei | Director, BD And AM | Leadership |
Jason Wang | Sr. Director, Strategy And Business Development | Leadership |
Eugene Surenkov | Procurement Director | Leadership |
Andrew Meadows | Senior Director, Human Resources | Leadership |
Aarif Khakoo | Chief Scientific Officer | Leadership |
Timothy Ingallinera | Director, Drug Product Development | Leadership |
Alison Lin | Director Of Fp&a | Leadership |
Shilpa S. | Vice President Process Science | Leadership |
Jenny Malecki | Executive Assistant To Chief Executive Officer | Leadership |
11 more people are available in the full profile.
Complete people profiles for Scribe Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Scribe Therapeutics
Scribe Therapeutics is a publicly listed company on the NASDAQ with ticker symbol SCTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Jul 2026
- Listed onNASDAQ: SCTX
- Listed entityScribe Therapeutics Inc.
- Exchange sectorHealth technology
- ISINUS8110331092
- Share price$19.23 (+9.45% on the day) · 2026-10-08
- Market capitalisation$364.1M
- Volume (last session)358,379
Timeline of Scribe Therapeutics
4 dated milestones of Scribe Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Scribe Therapeutics is founded.
- Funding First funding round of $20.0M.
- Funding Latest funding round, Series B, of $100.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Scribe Therapeutics
Scribe Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beam Therapeutics, eGenesis, Korro Bio, Metagenomi and Prime Medicine, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beamtx.com | 2017 | Cambridge, United States | $222M | 340 | Developer of gene therapy using CRISPR base editing to treat diseases | |
| egenesisbio.com | 2015 | Cambridge, United States | $481.42M | 94 | Gene transplantation platform for humanizing pig cells is developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| metagenomi.co | 2016 | Berkeley, United States | $376.37M | – | Next-generation gene editing tools are developed for drug enhancement. | |
| primemedicine.com | 2019 | Cambridge, United States | $200M | 214 | Genetic therapies for diseases are developed using prime editing technology. | |
| tesseratherapeutics.com | 2017 | Cambridge, United States | $610M | 149 | New genome engineering technology is provided for treating multiple diseases. | |
| eligo.bio | 2014 | Paris, France | $52.26M | – | In vivo gene editing technology is developed for microbiome modulation. | |
| locus-bio.com | 2015 | Raleigh, United States | $67.33M | 74 | Developer of therapeutics for infectious disease and inflammatory indications |
Detailed competitors of Scribe Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Scribe Therapeutics
The website of Scribe Therapeutics (scribetx.com) receives about 7.8K visits a month and ranks #3,256,959 among all websites worldwide, #4,283 in Biotechnology and Pharmaceuticals.
- Monthly visits7.8K
▲ 26.5% vs previous month
- Unique visitors2.4K
per month
- Global rank#3,256,959
among all websites
- Category rank#4,283
Health · Biotechnology and Pharmaceuticals
- Bounce rate47%
- Pages per visit1.6
- Average visit1 min 41 sec
- DevicesDesktop 50% · Mobile 50%
Latest news on Scribe Therapeutics
Complete news archive for Scribe Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Scribe Therapeutics
10 companies that operate in the same segment as Scribe Therapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Scribe Therapeutics
Scribe Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Scribe Therapeutics is headquartered in Alameda, United States. It is registered at Alameda, California, United States.
Scribe Therapeutics is a funded company, having raised a total of $120M across 2 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Oct 2020.
Founded in 2018 and headquartered in Alameda, United States, Scribe Therapeutics operates in the biotechnology sector. A proprietary X-editing (XE) platform, utilizing CRISPR technology and CasX enzymes with guide RNAs, is employed for in vivo genome modifications. Targeted genetic diseases include neurological and ophthalmological conditions, hematopoietic disorders, and applications in cell therapy. The platform enables precise gene knock-in or knock-out to address these health challenges.
Scribe Therapeutics's top competitors include eGenesis, Tessera Therapeutics and Korro Bio.
Scribe Therapeutics offers CRISPR-based Therapeutics and Epigenetic Long-Term X-Repressor Technology.
Yes, Scribe Therapeutics is publicly traded on NASDAQ under the ticker symbol SCTX.
Scribe Therapeutics has 8 investors. Key investors include T. Rowe Price, Orbimed, RA Capital, Perceptive Advisors, and Avoro Capital Advisors.